<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Metoprolol - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Metoprolol</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../index.html">Home</a>
        <a class="btn small" href="../medications.html">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Cardiac / Vascular</div>
      <h1>Metoprolol</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Metoprolol 25mg Tablets</li>
          <li>Metoprolol 5mg/5mL Injection 5mL</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <p><strong>Symptomatic atrial fibrillation/flutter with rapid ventricular response (rate control; when appropriate)</strong></p>
        <ul>
          <li>IV: 5 mg slow IV push; may repeat every 5 minutes to a maximum of 15 mg (or earlier if target HR reached or hypotension develops)</li>
          <li>PO (when stable/appropriate): 25–50 mg PO; repeat/titrate per response and local protocol</li>
        </ul>
        <p><strong>Suspected ACS / ischemic chest pain (selected patients; protocol-dependent)</strong></p>
        <ul>
          <li>IV: 5 mg slow IV push; may repeat every 5 minutes up to 15 mg if no contraindications</li>
          <li>PO: 25–50 mg PO when stable/appropriate; ongoing dosing per local protocol/medical direction</li>
        </ul>
        <p><strong>Hypertension / angina (ongoing therapy; provider-directed)</strong></p>
        <ul>
          <li>Typical range: 25–50 mg PO once to twice daily; titrate per BP/HR and tolerance (local guidance)</li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Rate control for atrial fibrillation/flutter or other supraventricular tachyarrhythmias (protocol-dependent)</li>
          <li>Adjunct therapy in ischemic heart disease/ACS in appropriate patients</li>
          <li>Hypertension and angina (ongoing/chronic management)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Bradycardia, hypotension, or shock</li>
          <li>2nd/3rd degree AV block or sick sinus syndrome (unless paced)</li>
          <li>Acute decompensated heart failure / cardiogenic shock</li>
          <li>Severe bronchospasm/asthma (risk of bronchospasm; use caution)</li>
          <li>Caution with diabetes (can mask hypoglycemia symptoms) and with other AV-nodal blockers (e.g., diltiazem/verapamil/digoxin/amiodarone) due to bradycardia/heart block risk</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Bradycardia, hypotension, dizziness/syncope</li>
          <li>Worsening heart failure (fluid retention, dyspnea) in susceptible patients</li>
          <li>Bronchospasm (susceptible patients)</li>
          <li>Fatigue</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <p><strong>IV formulation: 5 mg/5 mL (1 mg/mL)</strong></p>
        <ul>
          <li>Give slow IV push with continuous ECG/BP monitoring</li>
          <li>Stop/escalate reassessment if significant hypotension, bradycardia, heart block, or bronchospasm occurs</li>
        </ul>
        <p><strong>PO tablets (25 mg)</strong></p>
        <ul>
          <li>Give with food when feasible; reassess HR/BP after dosing</li>
          <li>Avoid rapid "stacking" of doses without reassessment</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Continuous ECG/telemetry (when available), HR, BP, SpO2</li>
          <li>Watch for bradycardia/AV block, hypotension, bronchospasm, and signs of heart failure</li>
          <li>If diabetic: monitor glucose closely if clinically relevant</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Use conservative dosing when monitoring capability is limited</li>
          <li>Ensure readiness to manage adverse effects (fluids/vasopressors per protocol; pacing capability if bradycardia/heart block risk)</li>
          <li>Document cumulative IV dose and response clearly to avoid dose stacking during handovers</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (metoprolol tartrate): https://pdf.hres.ca/dpd_pm/00060618.PDF</li>
          <li>BCEHS drug monograph (metoprolol): https://handbook.bcehs.ca/drug-monographs/metoprolol/</li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
